Venetoclax Based Regimen for R/R T-ALL
Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Sponsor: Affiliated Hospital of Nantong University
A PHASE2 clinical study on Acute T-Lymphocytic Leukemia, this trial is completed. The trial is conducted by Affiliated Hospital of Nantong University and has accumulated 9 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
May 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Jan 2022 — May 2023 [monthly]
Recruiting PHASE2
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Hospital of Nantong University
- Canglang Hospital of Suzhou
- Jining Medical University
- Nanyang Central Hospital of Henan Province
- Southern Medical University, China
- Suzhou Hospital of Traditional Chinese Medicine
- The First Affiliated Hospital of Anhui Medical University
- The First Affiliated Hospital of Bengbu Medical University
- The First Affiliated Hospital of Soochow University
- The Second People's Hospital of Huai'an
For direct contact, visit the study record on ClinicalTrials.gov .